Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

New therapies increase survival rates in post-transplant liver cancer patients

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

25 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

CT colonography screening identifies unsuspected cancer outside of colon

A new, large-scale study of more than 10,000 adults found that more than one in every 200 asymptomatic people screened with CT colonography, or virtual colonoscopy, had clinically unsuspected malignant cancer and more than half of the cancers were located outside the colon. The findings were published in the April issue of the journal Radiology.

23 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

17 Mar 2010

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Some of the most controversial issues in urology will be discussed by leading experts during the five-day 25th Annual Congress of the European Association of Urology in the Fira Barcelona congress venue in Barcelona (ES). From April 16 to 20, close to 12,000 participants and 3,000 company representatives are expected to gather in one of the world's biggest annual professional meetings in urology.

17 Mar 2010

NCCN Guidelines translated into Japanese

The NCCN Clinical Practice Guidelines in Oncology have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online.

17 Mar 2010

PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients

PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.

16 Mar 2010

Impact of tumor surgery on sexual function

Sexual problems are frequent after operations for carcinoma of the rectum. Christian Schmidt et al. describe the consequences for quality of life in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]: 123-30).

15 Mar 2010

Medafor, Magle Life Sciences of Sweden sign long-term raw material supply agreement

Medafor Inc. announced today that it has signed a long-term raw material supply agreement with Magle Life Sciences of Sweden, the supplier of the key powder component for Medafor’s patented MPH(R) (Microporous Polysaccharide Hemosphere) surgical product, which is used by surgeons to control bleeding in complex surgical operations.

15 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug

Medivir AB (Sweden) today announced a license agreement with Daewoong Pharmaceutical Co. Ltd., (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).

12 Mar 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010

Iraqi National Cancer Research Program established to curb rising incidence of breast cancer

Breast cancer continues to rise in Iraq, and scientists have established the Iraqi National Cancer Research Program to better understand the underlying molecular and environmental causes in an effort to curb the incidence of cancer.

11 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

The Journal of the American Academy of Dermatology (JAAD) has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses - 2.5% and 3.75% - administered daily on a 2-week treatment cycle. The study demonstrates that both formulations were superior to placebo, and that imiquimod 3.75% on a daily 2-week treatment cycle is superior to imiquimod 2.5% in treating actinic keratosis (AK) on a large surface area - the face or balding scalp.

9 Mar 2010

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

The Journal of the American Academy of Dermatology has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses – 2.5% and 3.75% – administered daily on either 2-week or 3-week treatment cycles.

9 Mar 2010

Carcinoma News and Research

Further Reading

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

New therapies increase survival rates in post-transplant liver cancer patients

Æterna Zentaris announces 2009 financial and operating results

CT colonography screening identifies unsuspected cancer outside of colon

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Most controversial issues in urology to be discussed in the Annual Congress of EAU

NCCN Guidelines translated into Japanese

PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients

Impact of tumor surgery on sexual function

Medafor, Magle Life Sciences of Sweden sign long-term raw material supply agreement

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

Iraqi National Cancer Research Program established to curb rising incidence of breast cancer

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News